TTA-P2 (Standard)

TTA-P2 (Standard) is the analytical standard of TTA-P2 (HY-10035) . This product is intended for research and analytical applications. TTA-P2 (T-Type calcium channel inhibitor) is a selective, orally active, and BBB-penetrant T-type calcium channel blocker (IC50 = 22 nM) . TTA-P2 reduces mechanical hypersensitivity and alleviates acute as well as chronic pain. TTA-P2 significantly reduces firing rates in temporal lobe epilepsy (TLE) neurons to control levels and suppresses synaptically evoked burst firing. TTA-P2 can be studied in research for neurological diseases such as tremor and absence epilepsy[1][2][3][4][5].

Product Specifications

CAS Number

[1072018-68-8]

Target

Calcium Channel; Reference Standards

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Field of Research

Neurological Disease

Smiles

CC(C)(OCC1)C[C@H]1CN2CCC(F)(CC2)CNC(C3=CC(Cl)=CC(Cl)=C3)=O

Molecular Formula

C21H29Cl2FN2O2

Molecular Weight

431.37

References & Citations

[1]Huilin Liu, et al., Inhibition of T-Type Calcium Channels With TTA-P2 Reduces Chronic Neuropathic Pain Following Spinal Cord Injury in Rats, The Journal of Pain, Volume 24, Issue 9, 2023, Pages 1681-1695, ISSN 1526-5900.|[2]WonJoo Choe, et al., TTA-P2 Is a Potent and Selective Blocker of T-Type Calcium Channels in Rat Sensory Neurons and a Novel Antinociceptive Agent, Molecular Pharmacology, Volume 80, Issue 5, 2011, Pages 900-910, ISSN 0026-895X.|[3]Dreyfus, F. M., et al., (2010) . Selective T-type calcium channel block in thalamic neurons reveals channel redundancy and physiological impact of I (T) window. The Journal of neuroscience : the official journal of the Society for Neuroscience, 30 (1), 99-109.|[4]Nigam, A., et al., (2019) . Inhibition of T-Type calcium channels in mEC layer II stellate neurons reduces neuronal hyperexcitability associated with epilepsy. Epilepsy research, 154, 132-138.|[5]Shipe, W. D., et al., (2008) . Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. Journal of medicinal chemistry, 51 (13), 3692-3695.